These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 4817854)
1. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition. Sandler M; Johnson RD; Ruthven CR; Reid JL; Calne DB Nature; 1974 Feb; 247(5440):364-6. PubMed ID: 4817854 [No Abstract] [Full Text] [Related]
2. Inhibition of a minor pathway of L-dopa metabolism in the intestinal lumen using a decarboxylase inhibitor (Ro 4-4602). Bakke OM; Scheline RR J Pharm Pharmacol; 1974 May; 26(5):377-9. PubMed ID: 4152920 [No Abstract] [Full Text] [Related]
3. Suppression of noradrenaline synthesis in sympathetic nerves by carbidopa, an inhibitor of peripheral dopa decarboxylase. Wurtman RJ; Watkins CJ Nature; 1977 Jan; 265(5589):79-80. PubMed ID: 834247 [No Abstract] [Full Text] [Related]
4. Carbidopa attenuation of L-DOPA emesis in dogs: evidence for a cerebral site of action outside the blood-brain barrier. Lotti VJ; Clark C Eur J Pharmacol; 1974 Mar; 25(3):322-5. PubMed ID: 4827858 [No Abstract] [Full Text] [Related]
6. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease. Ebinger G; Adriaenssens K Clin Chim Acta; 1973 Nov; 48(4):427-31. PubMed ID: 4761590 [No Abstract] [Full Text] [Related]
7. [Parkinsonism and plasma metabolism of dihydroxyphenylalanine administered with an inhibitor of decarboxylase]. Geissbühler F; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R Clin Chim Acta; 1971 Jun; 33(1):111-5. PubMed ID: 5097993 [No Abstract] [Full Text] [Related]
8. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)]. Yoshimine N; Kuzuya F; Mori K; Sakamoto N Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010 [No Abstract] [Full Text] [Related]
9. Aterial blood pressure in dogs: effects of m-tyrosine alone or in combination with inhibitors of aromatic amino acid decarboxylase; relative hypotensive potencies of L-dopa, DL-m-tyrosine, and L-m-tyrosine. Minsker DH; Stokes AL Experientia; 1974 Sep; 30(9):1051-3. PubMed ID: 4412113 [No Abstract] [Full Text] [Related]
10. [Urinary excretion of 3,4-dihydroxyphenyl-alanine, 3-O-methyldopa, dopamine and homovanillic acid in man. Effects of an inhibitor of decarboxylase of aromatic amino acids (Benserazide) (author's transl)]. Geissbühler F; Widmer J J Clin Chem Clin Biochem; 1976 Nov; 14(11):543-7. PubMed ID: 1003116 [TBL] [Abstract][Full Text] [Related]
12. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa. Bianchine JR; Messiha FS; Hsu TH Clin Pharmacol Ther; 1972; 13(4):584-94. PubMed ID: 5042372 [No Abstract] [Full Text] [Related]
13. The influence of L-DOPA perfusion concentrations and peripheral decarboxylase inhibition on dopa accumulation and decarboxylation in isolated perfused rat brains. Horst WD; Bautz G; Renyi E; Spirt N Neuropharmacology; 1973 Dec; 12(12):1145-51. PubMed ID: 4782694 [No Abstract] [Full Text] [Related]
14. Brain capillaries as a source of homovanillic acid in cerebrospinal fluid. Bartholini G; Tissot R; Pletscher A Brain Res; 1971 Mar; 27(1):163-8. PubMed ID: 5554221 [No Abstract] [Full Text] [Related]
15. Effect of carbidopa on the metabolism of L-dopa in the pigtail monkey. Bronaugh RL; Wenger GR; Garver DL; Rutledge CO Biochem Pharmacol; 1976 Jul; 25(14):1679-81. PubMed ID: 821489 [No Abstract] [Full Text] [Related]
16. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease. Mars H Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941 [No Abstract] [Full Text] [Related]